BCRX Stock Analysis: Buy, Sell, or Hold?
BCRX - BioCryst Pharmaceuticals Inc
$9.29
0.18 (2.03%)
▲
5d:
-11.1%
30d:
+4.15%
90d:
-2.42%
WAIT
LOW Confidence
Analysis Updated: Jul 17, 2026 12:00 AM ET
Earnings: Aug 03, 2026
15d
Smart Money Accumulation
None View Scanner →
Strength: 8.0/10
Get Alerted When BCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BCRX is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BCRX is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$29.18
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$18.12
48.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BCRX is currently trading at $9.29, which is considered fair relative to its 30-day fair value range of $8.75 to $10.27. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.0) compared to its historical average (16.2). Remarkably, the market is currently pricing in an annual earnings decline of 14.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BCRX is in a uptrend. Immediate support is located at $8.95, while resistance sits at $11.22.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.00 (+126.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCRX is in a uptrend. Immediate support is located at $8.95, while resistance sits at $11.22.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.00 (+126.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.75 -
$10.27
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
Protect Your Profits
Holding BCRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 126.0% below Wall St target ($21.00)
- WARNING: Recommendation downgraded due to -11.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$8.75 -
$10.27
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$8.95
Resistance Level
$11.22
Current Trend
Uptrend
Technical data as of
Jul 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.04
Wall Street Target
$21.00
(+126.0%)
Revenue Growth (YoY)
7.5%
Profit Margin
-51.7%
Valuation Discount vs History
-14.7% cheaper
PE vs Historical
10.0 vs 16.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.7%
(market-implied from PE analysis)
1-Year Target
$8.36
(-10%)
2-Year Target
$7.52
(-19%)
3-Year Target
$6.77
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→16)
$10.92
(+18%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.0, Growth: 51.6%)
$65.59
(+606%)
Base:
(SPY PE: 10.0, Growth: 51.6%)
$31.35
(+238%)
Bear:
(PE: 8.5, Growth: 51.6%)
$26.65
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.0 to 16.2
Stabilization Target:
$14.98
(+61.3%)
PE Expansion Potential:
+61.3%
Share & Embed Analysis
Last updated: July 18, 2026 5:25 PM ET
Data refreshes hourly during market hours. Next update: 6:25 PM
Data refreshes hourly during market hours. Next update: 6:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alane P Barnes
SELL
150000 shares
2026-03-16
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 64 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 61 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 53 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced BCRX Option Strategies
Professional options setups generated by AI based on today's BCRX price and gamma walls.
